Efficacy of Lanthanum Carbonate on Hyperphosphatemia in Maintenance Hemodialysis Patients and its Effect on Left Ventricular Hypertrophy and Microinflammation

The aim of this study was to investigate the efficacy of lanthanum carbonate on hyperphosphatemia in maintenance dialysis patients and its effect on left ventricular hypertrophy and microinflammation. Sixty hyperphosphatemia patients receiving maintenance hemodialysis were randomly divided into calcium acetate and lanthanum carbonat groups, with 30 cases in each group. Base on the high-flux hemodialysis, the calcium acetate group was treated with calcium acetate capsules, and the lanthanum carbonate group was treated with lanthanum carbonate chewable tablets. After six months of treatment, compared with calcium acetate group, in lanthanum carbonate group the total effective rate was significantly increased, the serum calcium, phosphorus and intact parathyroid hormone levels were significantly decreased, the left ventricular mass index was significantly decreased, and the serum tumor necrosis factor a, interleukin 6 and high-sensitivity C-reactive protein levels were significantly decreased. In conclusion, lanthanum carbonate can effectively alleviate the hyperphosphatemia in maintenance hemodialysis patients, delay the left ventricular hypertrophy, and reduce the microinflammatory state.

Automated summary

The aim of this study was to investigate the efficacy of lanthanum carbonate in treating hyperphosphatemia in maintenance dialysis patients and its impact on left ventricular hypertrophy and microinflammation. The results showed that lanthanum carbonate can effectively alleviate hyperphosphatemia and reduce left ventricular hypertrophy and microinflammatory state.